Practice Areas - Corporate and M&A Law Firms and Lawyers
| Deal Date: | 09-06-2020 | Practice Area: | Corporate and M&A |
| Deal Title: | CSL Behring Acquisition of Vitaeris | Industry: | Pharmaceuticals & Biotechnology |
| Description: |
Simpson Thacher represented CSL Behring in connection with its acquisition of Vitaeris Inc., a clinical-stage biotechnology company focused on the phase III development of clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody (MAB), for the potential treatment of chronic active antibody-mediated rejection (AMR), the leading cause of long-term rejection in kidney transplant recipients. The companies entered into a strategic partnership in 2017 to expedite the development of clazakizumab with the option for CSL Behring to acquire Vitaeris, along with this important product candidate.
|
||
| Financial Center: | New York | Value: | 0.00-0.00 |
| Advised Party: | Acquiror | Law Firm | Simpson Thacher |
| Target Company Jurisdiction: | United States | Acquiror Jurisdiction: | United States |
| Classification: |
Strategic Buyer Acquisitions Private Company |
Lawyer | Mark D Pflug |
